| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | insulin glargine/lixisenatide (Suliqua®) |
| Formulation | 100 units/ml 33 micrograms/ml and 100 units/ml 50 micrograms/ml solution for injection |
| Reference number | 2464 |
| Indication | Treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 01/08/2019 |